Stay updated with breaking news from Roche Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BALTIMORE, Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics company, has entered into a collaboration with Alliance Foundation Trials, LLC for research use of Haystack...
Dosing XTX301 at 45 ug/kg once every three weeks in ongoing Phase 1 trial, nearly 100x the maximum tolerated dose of rhIL-12, with no dose-limiting toxicities observed to date Initiated patient...
Dosing XTX301 at 45 ug/kg once every three weeks (dose level 3) in ongoing Phase 1 trial, nearly 100x the maximum tolerated dose of rhIL-12, with no dose-limiting toxicities observed
/PRNewswire/ -- Frontage Laboratories, Inc. today announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition...
The transformative point of care solution will complement Roche’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease...